These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37874427)

  • 1. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
    Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
    Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
    Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
    J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinoma.
    Grochowski P; Grosser B; Sommer F; Probst A; Waidhauser J; Schenkirsch G; Reitsam NG; Märkl B
    BMC Cancer; 2024 Jun; 24(1):768. PubMed ID: 38926671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Converging deep learning and human-observed tumor-adipocyte interaction as a biomarker in colorectal cancer.
    Reitsam NG; Grosser B; Steiner DF; Grozdanov V; Wulczyn E; L'Imperio V; Plass M; Müller H; Zatloukal K; Muti HS; Kather JN; Märkl B
    Commun Med (Lond); 2024 Aug; 4(1):163. PubMed ID: 39147895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
    Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between Stroma AReactive Invasion Front Areas (SARIFA), Warburg-subtype and survival: results from a large prospective series of colorectal cancer patients.
    Offermans K; Reitsam NG; Simons CCJM; Grosser B; Zimmermann J; Grabsch HI; Märkl B; van den Brandt PA
    Cancer Metab; 2024 Jul; 12(1):21. PubMed ID: 38992781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
    Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
    Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
    Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
    Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
    BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
    Ulase D; Behrens HM; Röcken C
    Virchows Arch; 2024 Sep; 485(3):527-534. PubMed ID: 38748262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
    Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
    Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
    Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
    Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SARIFA biomarker in the context of basic research of lipid-driven cancers.
    Märkl B; Reitsam NG; Grochowski P; Waidhauser J; Grosser B
    NPJ Precis Oncol; 2024 Jul; 8(1):165. PubMed ID: 39085485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study.
    Hu Q; Wang Y; Yao S; Mao Y; Liu L; Li Z; Chen Y; Zhang S; Li Q; Zhao Y; Fan X; Cui Y; Zhao K; Liu Z
    Cancer Res Commun; 2023 Jun; 3(6):1057-1066. PubMed ID: 37377615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cell-mediated immune surveillance in cancer: Role of tumor microenvironment.
    Saadh MJ; Rasulova I; Khalil M; Farahim F; Sârbu I; Ciongradi CI; Omar TM; Alhili A; Jawad MJ; Hani T; Ali T; Lakshmaiya N
    Pathol Res Pract; 2024 Feb; 254():155120. PubMed ID: 38280274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer.
    Gu W; Sun H; Zhang M; Mo S; Tan C; Ni S; Yang Z; Wang Y; Sheng W; Wang L
    Cancer Med; 2023 Jan; 12(2):1520-1531. PubMed ID: 35864742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.
    Sakurai M; Miki Y; Takagi K; Suzuki T; Ishida T; Ohuchi N; Sasano H
    Breast Cancer Res; 2017 Jun; 19(1):70. PubMed ID: 28629450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value and Immune Infiltrates of ABCA8 and FABP4 in Stomach Adenocarcinoma.
    Guo Y; Wang ZW; Su WH; Chen J; Wang YL
    Biomed Res Int; 2020; 2020():4145164. PubMed ID: 32685482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis.
    Zheng HC; Takahashi H; Murai Y; Cui ZG; Nomoto K; Miwa S; Tsuneyama K; Takano Y
    Br J Cancer; 2006 Nov; 95(10):1371-8. PubMed ID: 17088917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.